Current Clinical Trials for Plantar Fasciitis
Here is the promised article about randomized double-blind clinical trials that relate to Plantar Fasciitis. This article will discuss the current ongoing clinical trials for plantar fasciitis and/or fasciosis. For some, this information will be better than gold. There will be information given for three test studies that are currently recruiting participants. The first one is the Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis, the second is Efficacy of the TOPAZ™ Microdebridement Procedure for Treating Plantar Fasciosis, and the third is Conservative Treatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports.
The purpose of the Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis, is to find out if one single injection of Dysport (200 MU) will result in a significant reduction in the symptoms of plantar fasciitis.
They will be accepting 40 participants. This study is open to both males and females over the age of 18. The criteria includes the requirement of diagnosed plantar fasciitis for at least four months or longer, at least two previous unsuccessful conservative therapies, and pain within the previous 48 hours.
Rheumatoid disease is cause for exclusion as well as previous surgery in the affected foot.
The following locations are conducting this scientific study:
- University Hospital Charite, Musculoskeletal Centre, Berlin, Germany
- Orthopedic Practice, Weiden,Germany
- Orthopedic Practice, Karlsruhe, Germany
- Orthocentre Munich, Munich, Germany
- Orthopedic Practice Biberburg, Berlin, Germany
The Microdebridement Procedure for Treating Plantar Fasciosis is actually a post-surgery procedure for patients who have evidence of plantar fasciosis–degenerative process of the fascia.
Ninety healthy participants, male or female, between the ages of 18 and 65 will be accepted for inclusion in the study. Thickening of the plantar fascia is a requirement.
Candidates who have used NSAID’s such as Naprosyn or Ibuprofen during the previous two weeks, a history of diabetes types I and II, history of fibromyalgia, autoimmune disease, previous fascia surgery, or any infection, tumor, or pregnancy will be excluded.
Anyone interested in participitating in this study can contact one of the following clinics:
- Foot Care Physicians, Mesa, Arizona 85204
- Reisha Zang 480-834-8804 email@example.com
- Bruce Werber, DPM 480-834-8804 firstname.lastname@example.org
- Foot and Ankle Institute of Santa Monica, Santa Monica California 90403
- Nubia Diaz 310-828-0011 email@example.com
- Babak Baravarian, DPM 310-828-0011
- Foot and Ankle Clinic of Oakwood, Oakwood, Georgia 30566
- Cathy Rowan 770-536-7008 firstname.lastname@example.org
- Thomas Brosky, II, DPM 770-535-1212 email@example.com
- Ankle and Foot Specialist of Atlanta, Lithonia, Georgia, 30058
- Arletha White 770-981-9011 firstname.lastname@example.org
- Arlington Foot Center, Arlington, Texas 76014
- Joe T. Southerland, DPM 817-467-1990 email@example.com
- Fredericksburg Foot & Ankle Center, Fredericksburg, Virginia 22408
- Ross J. Girvan, DPM 540-374-5261 firstname.lastname@example.org
The third and final clinical trial is Conservative Treatment of Plantar Fasciitis With
Dorsiflexion Night Splints and Medial Arch Supports. The purpose of this study is to compare the difference between the combined effect of both dorsiflexion night splints and medial arch supports in comparison the effect of splints and supports individually in the treatment of plantar fasciitis.
Eligiblity for this test is participants over the age of 18 and is open to both male and female with plantar heel pain. Some of the conditions that will be excluded include gout, lupus, rheumatoid arthritis, ankylosing spondylitis, tarsal tunnel syndrome, or loss of plantar foot sensation.
For more information about participation in this study you can contact:
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
- Ahmad H Alghadir, MS, PT 412-726-1826 email@example.com
- James J Irrgang, PhD, PT 412-647-1237 firstname.lastname@example.org
And for now…
This concludes my plantar fasciitis discussion.
U.S. National Library of Medicine
National Institutes of Health